Bigfoot Biomedical‘s chief executive is excited about Abbott‘s (NYSE:ABT) latest regulatory win – and it’s not just because the two companies have an established partnership.
Yesterday, the FDA approved Abbott’s FreeStyle Libre Flash continuous glucose monitoring system. It’s the first device of its kind, allowing patients to track their blood glucose levels without the use of routine finger sticks.
“It’s a tremendous demonstration that the FDA understands the value of factory calibration and making usage of a sensor simpler and easier,” Bigfoot CEO Jeffrey Brewer told Drug Delivery Business News.
Get the full story at our sister site, Drug Delivery Business News.
The post Why Bigfoot Biomedical’s CEO thinks the diabetes industry has a data problem appeared first on MassDevice.
from MassDevice http://ift.tt/2fxv9ZS
Cap comentari:
Publica un comentari a l'entrada